Keral

Dexketoprofen, the active ingredient in Keral, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for systemic use. It is indicated for the relief of mild to moderate pain, including musculoskeletal discomfort, postoperative pain and dysmenorrhea, and is used in adult patients requiring rapid analgesia.

GNH USA supplies Keral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Dexketoprofen is an NSAID that reduces pain and inflammation by inhibiting cyclooxygenase enzymes.

- Mild to moderate pain: provides rapid analgesic relief for general pain conditions. - Musculoskeletal pain: alleviates pain associated with strains, sprains and arthritis. - Postoperative pain: helps control pain after surgical procedures. - Dysmenorrhea: reduces menstrual cramps and associated discomfort.

Dexketoprofen may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia. - Nausea or vomiting. - Headache. - Dizziness.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Acute renal impairment or worsening of chronic kidney disease. - Severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Dexketoprofen, clinicians should consider several safety factors.

- Assess renal function: evaluate kidney health prior to initiation. - Monitor gastrointestinal risk: avoid in patients with a history of ulcers or bleeding. - Avoid concomitant NSAIDs: combined use increases risk of adverse events. - Use lowest effective dose: limit duration to the shortest necessary period. - Store at ambient temperature: keep below 25 °C, in the original pack, protected from moisture.

Dexketoprofen can interact with several drug classes, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Selective COX‑2 inhibitors: additive renal and cardiovascular toxicity. - Corticosteroids: increased gastrointestinal ulcer risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Lithium: NSAIDs may raise lithium serum levels. - Methotrexate: reduced clearance may cause toxicity.